Julia Neugebauer | Senior Director, Investor Relations |
Jean-Paul Kress | Chief Executive Officer |
Sung Lee | Chief Financial Officer |
Roland Wandeler | Chief Operating Officer |
Malte Peters | Chief Research and Development Officer |
James Quigley | Morgan Stanley |
Zhiqiang Shu | Berenberg |
Roy Buchanan | JMP Securities |
Etzer Darout | Guggenheim Securities |
Graig Suvannavejh | Goldman Sachs |
James Gordon | JPMorgan |
Ladies and gentlemen, good afternoon or good morning. My name is Julia Neugebauer, Senior Director, Investor Relations at MorphoSys and it is my pleasure to welcome you to our Second Quarter 2021 Financial Results Conference Call.
Joining me on the call today are Jean-Paul Kress, Chief Executive Officer; Sung Lee, Chief Financial Officer; Roland Wandeler, Chief Operating Officer; and Malte Peters, Chief Research and Development Officer.
Before we begin, I would like to remind you on Slide 2 that some of the statements made during the call today are forward-looking statements, including statements regarding our expectations for the commercialization of our products and our development plans, the impact of COVID-19 on our business and expectations for the compounds in our pipeline, as well as the development plans of our collaboration partners. These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in MorphoSys’ 20-F and Annual Report or for the year ended December 31, 2020 and from time-to-time in other SEC documents at MorphoSys.